Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v11-EN | Version v8-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2022-03-19 | 2022-03-18 |
| Drug Identification Number | 02242905 | 02242905 |
| Brand name | MIDAZOLAM INJECTION | MIDAZOLAM INJECTION |
| Common or Proper name | Midazolam Injection 5 mg/mL MD Vial 10 mL | Midazolam Injection 5 mg/mL MD Vial 10 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | MIDAZOLAM | MIDAZOLAM |
| Strength(s) | 5MG | 5MG |
| Dosage form(s) | LIQUID | LIQUID |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 10 mL | 10 mL |
| ATC code | N05CD | N05CD |
| ATC description | HYPNOTICS AND SEDATIVES | HYPNOTICS AND SEDATIVES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-01-01 | 2022-01-01 |
| Actual start date | ||
| Estimated end date | 2022-03-18 | 2022-03-18 |
| Actual end date | 2022-03-18 | 2022-03-18 |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Midazolam Injection 5 mg/mL MD Vial 10 mL effective January 1, 2022 until January 31, 2022. | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Midazolam Injection 5 mg/mL MD Vial 10 mL effective January 1, 2022 until January 31, 2022. |
| Health Canada comments |